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Abstract
The kappa opioid receptor (KOR) is involved in mediating pruritus; agonists targeting this 
receptor have been used to treat chronic intractable itch. Conversely, antagonists induce an inch 
response at the site of injection. As a G protein-coupled receptor (GPCR), the KOR has potential 
for signaling via G proteins and βarrestins, however, it is not clear which of these pathways are 
involved in the KOR modulation of itch. In this study asked whether the actions of KOR in 
pruritus involve βarrestins by using βarrestin2 knockout (βarr2-KO) mice as well as a recently 
described biased KOR agonist that biases receptor signaling toward G protein pathways over 
βarrestin2 recruitment. We find that the KOR antagonists nor-binaltorphimine (NorBNI) and 5′-
guanidinonaltrindole (5′GNTI) induce acute pruritus in C57BL/6J mice, with reduced effects in 
KOR-KO mice. βarr2-KO mice display less of a response to KOR antagonist-induced itch 
compared to wild types, however no genotype differences are observed from chloroquine 
phosphate (CP)-induced itch, suggesting that the antagonists may utilize a KOR-βarrestin2 
dependent mechanism. The KOR agonist U50,488H was equally effective in both WT and βarr2-
KO mice in suppressing CP-induced itch. Furthermore, the G protein biased agonist, 
Isoquinolinone 2.1 was as effective as U50,488H in suppressing the itch response induced by 
KOR antagonist NorBNI or CP in C57BL/6J mice. Together these data suggest that the 
antipruritic effects of KOR agonists may not require βarrestins.
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Pruritus, commonly referred to as itch, is defined as “an unpleasant cutaneous sensation that 
provokes the desire to scratch” (Rothman, 1941). Pruritus secondary to disease can become 
pathological, resulting in an intense, chronic itch that can have a significantly negative 
impact on quality of life. Unfortunately, there are few therapeutic options for those that 
suffer from severe pathological itch. Recent advances in the understanding of the biology of 
pruritus implicate dynorphin and the kappa opioid receptor (KOR) as a potential therapeutic 
target (Kardon et al., 2014; Ross et al., 2010; Sardella et al., 2011) leading to new 
therapeutic options utilizing KOR agonists.
The KOR is a seven transmembrane G protein coupled receptor (GPCR) that is expressed 
throughout the nervous system. Elegant studies from the Ross laboratory demonstrate a 
functional role for KOR on dorsal root ganglion neurons for modulating itch responses 
(Kardon et al., 2014). Activation of KOR results in signaling through the pertussis toxin-
sensitive Gαi/o proteins to inhibit adenylyl cyclase (Sharma et al., 1977), activate inward-
rectifying potassium channels (North et al., 1987), inhibit voltage-dependent calcium 
channels (Hescheler et al., 1987; Surprenant et al., 1990) and increase intracellular calcium 
levels (Jin et al., 1992). However, it is becoming increasingly evident that GPCRs can signal 
via multiple downstream effectors, including other Gα protein subunits and βarrestins. 
βarrestins are multifunctional scaffolding proteins that can serve to scaffold to receptors 
thereby facilitating certain protein-protein interactions while disrupting others. In this role, 
βarrestins can serve to dampen or facilitate receptor signaling to downstream effectors. It has 
been suggested that KOR can also signal via βarrestins and shown that U69,593-mediated 
KOR activation of ERK1/2 is impaired in mice lacking βarrestin2 (βarr2-KO mice) (Schmid 
et al., 2013).
Receptors can conceptually interact with different G proteins and/or βarrestins to propagate 
downstream signaling, and certain agonists can facilitate signaling to one cascade over 
another. Therefore an opportunity arises to divert receptor signaling towards one cascade or 
another in an effort to harness receptor signaling to induce desired physiologies and avoid 
unwanted effects. The KOR has proven to be capable of signaling via G proteins and 
βarrestins, and different ligands have proven to be better at generating signals through one of 
these cascades over the others. Such ligands, referred to as “biased agonists,” may prove to 
be therapeutically beneficial when the desired effects are known to be mediated by one 
pathway while the deleterious effects are mediated by another pathway.
There is emerging information regarding the potential for “ligand-directed signaling” at the 
KOR. Activation of KOR is associated with dysphoria, depression and anxiety, and effects 
related to drug relapse and pro-addictive behaviors and has been proposed to be dependent 
upon GPCR kinase 3 (GRK3)-dependent βarrestin interactions with the receptor (Bruchas 
and Chavkin, 2010; Bruchas et al., 2006). KOR activation has also been proposed as a 
means to provide pain relief and activation of KOR in this manner appears to be due to G 
protein mediated mechanisms (Bruchas et al., 2007; White et al., 2014). Recently, agonists 
that bias KOR signaling toward G protein signaling and away from βarrestin2 recruitment 
have been identified (Rives et al., 2012; Schmid et al., 2013; White et al., 2015; White et al., 
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2014; Zhou et al., 2013). These tools, as well as βarr2-KO mice, are serving to define which 
KOR signaling pathways can be attributed to G protein or βarrestin2 signaling mechanisms. 
Thus far, it is apparent that KOR signaling via G proteins is sufficient to provide 
antinociception (White et al., 2014; Zhou et al., 2013). However, the question of how KOR 
modulates itch responses remains.
The KOR agonist nalfurafine (Remitch®) is used in treatment of the pruritus associated with 
chronic renal failure in humans, with intravenous (Ueno et al., 2013; Wikstrom et al., 2005) 
and oral (Kumagai et al., 2012; Kumagai et al., 2010) efficacy. In hemodialysis patients, 
nalfurafine can produce long-term suppression of pruritus without significant safety issues 
(Kumagai et al., 2012) or abuse liability (Ueno et al., 2013). In mice, KOR agonists are also 
effective. For example, the KOR agonist U50,488H reduces scratching induced by 
compound 48/80 (Kamei and Nagase, 2001). Additionally, nalfurafine (also known as 
TRK-820) inhibits the development of pruritus induced by substance P (Togashi et al., 2002; 
Umeuchi et al., 2003), histamine (Togashi et al., 2002), chloroquine phosphate (Inan and 
Cowan, 2004), as well as compound 48/80 (Inan et al., 2009b; Wang et al., 2005). 
Nalfurafine is a potent partial agonist with weak efficacy and no studies to date have 
determined whether it possesses biased signaling properties.
Conversely, KOR antagonists such as nor-binaltorphimine (NorBNI) and 
5′guanadinonaltrindole (5′GNTI) induce acute pruritus (Inan t al., 2009a, b; Kamei and 
Nagase, 2001). Since the antagonists can induce itch it is attractive to speculate that the 
underlying tone of the endogenous KOR agonists, dynorphins, naturally suppress the itch 
response. However, the mechanisms by which KOR signaling modulates this response 
remains unclear, although recent reports have begun to uncover such mechanisms and 
confirm the importance of the KOR system (Kardon et al., 2014).
In this study, we ask whether βarrestins are involved in itch produced by KOR antagonists 
and whether the antipruritic effects of KOR agonists require βarrestin2. We utilize both 
βarr2-KO mice as well as a G protein biased KOR agonist, “Isoquinolinone 2.1” (Iso2.1), 
(Zhou et al., 2013). Iso2.1 produces more [35S]GTPγS binding than βarrestin2 recruitment 
(DiscoveRx PathHunter assay) with a calculated bias factor of 31. It has in vivo efficacy as it 
induces antinociception in the warm water tail immersion test (Zhou et al., 2013). Herein we 
test its function in a mouse model of pruritus.
2. Methods
2.1 Animals
Experiments were carried out with age matched (10-16 week old) male mice weighing 
between 25 and 35 g. C57BL/6J mice were purchased from Jackson Laboratory (Bar 
Harbor, ME); KOR-KO mice were purchased from Jackson Laboratory and generated from 
homozygous breeding; βarr2-WT and βarr2-KO mice were derived from heterozygous 
breeding as previously described (Bohn et al., 1999). Mice were group housed (3-5 mice per 
cage) and maintained on a 12-hour light/dark cycle in a temperature-controlled room. All 
behavioral tests were performed during the light cycle between 8am-6pm. All mice were 
cared for in accordance to the guidelines set forth by the National Institutes of Health 
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regarding the proper treatment and use of laboratory animals and with approval of The 
Scripps Research Institute Animal Care and Use Committee.
2.2 Drugs
Nor-Binaltorphimine (NorBNI), 5′-guanidinonaltrindole (5′GNTI) and chloroquine 
phosphate (CP) were purchased from Sigma-Aldrich (St. Louis, MO) and U50,488H was 
purchased from Tocris Bioscience (Ellisville, MO). The synthesis of Iso2.1 has been 
previously described (Zhou et al., 2013). All drugs were prepared in a vehicle consisting of 
1:1:8 dimethyl sulfoxide (DMSO), Tween80 and 0.9% sterile saline, with a pH of 6.0. 
Specifically, Iso2.1 was first dissolved in DMSO, then Tween80 and brought to volume with 
sterile saline; CP was first dissolved in 0.9% sterile saline and brought up to volume with 
DMSO and Tween80 to result in a 1:1:8 solution; pH 6.0. All drugs used to promote itch 
were freshly prepared and injected subcutaneously in the skin at the base of the neck 
(indicated by s.c.neck) at a volume of 5 μl/g body weight; KOR agonists used to block itch 
were injected subcutaneously (s.c.) in the flank area (5 μl/g body weight). When used as a 
pre-treatment, NorBNI was injected intraperitoneally (i.p.) at a volume of 10 μl/g body 
weight; dosing routes are indicated in the text. In order to conserve animals, all animals were 
pretreated with systemic injection of vehicle prior to treatments (10 minutes) so that separate 
groups would not be needed to compare to those animals receiving either agonist or 
antagonist pretreatments.
2.3 Evaluation of Pruritus-Induced Behavior
Mice were habituated to clear acrylic testing boxes [10 × 10 cm2] for one hour prior to the 
start of the experiment. All mice received a pretreatment of either vehicle (1:1:8 DMSO, 
Tween80, 0.9% sterile saline) or KOR agonists U50,488H or lso2.1 (5 μ/g, s.c). Ten minutes 
after pretreatment, mice receive a pruritogen injection (5 μ/g, s.c.neck) of either NorBNI, 
5′GNTI or CP to induce acute pruritus. Immediately after the pruritogen injection the 
number of scratching bouts are recorded every 5 minutes for 1 hour by an investigator 
blinded to the treatment groups. During the experiments, mice were videotaped and for some 
studies, another investigator repeated scoring to validate the method. A “scratching bout” is 
defined as one or more rapid paw movements directed at the injection site, with the hindpaw 
being placed back on the floor as previously described (Holmes et al., 2012).
2.4 Spontaneous locomotor activity
C57BL/6J male mice were monitored in an open field activity monitor (Versamax [20 × 20 
cm2] by Accuscan Instruments) immediately following injection (10 μ/g, s.c.) with vehicle, 
U50,488H or lso2.1 without habituation. In the twenty-four hour NorBNI pretreatment 
group, mice were injected with NorBNI (10 mg/kg, i.p.) and returned to the home cage until 
testing the following day. Spontaneous activity was measured over 60 minutes, with the 
number of horizontal beam breaks collected in 5-minute bins.
2.5 Statistical Analysis
All statistical comparisons were made using GraphPad Prism 6.01 software (GraphPad, 
LaJolla, CA) and are expressed as mean ± SEM. Differences between means were analyzed 
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by oneway ANOVA for comparisons within the same genotype and by two-way ANOVA 
for comparisons between genotypes and time-course evaluation. All ANOVAs were 
followed with Bonferroni post hoc analysis, and in all analyses significance is set at p < 
0.05.
3. Results
3.1 KOR antagonists NorBNI and 5′GNTI induce acute pruritus in C57BL/6J mice, with a 
reduced effect in KOR-KO mice
KOR antagonists have been characterized as acute pruritogen-inducing agents in ICR mice 
treated with NorBNI (Kamei and Nagase, 2001) and in Swiss Webster mice treated with 
5′GNTI (Inan et al., 2009b). Here we show that these antagonists also induce itch in the 
C57BL/6J mouse line. This strain was chosen as it serves as the parental strain for the KOR-
KO mice and is one of the parental strains of the βarr2-KO mice used later in this study. As 
seen in other strains of mice, these antagonists elicit a robust, dose-dependent increase in 
scratching behavior over the 60 minute observation period in adult male C57BL/6J mice 
compared to vehicle (Fig.1A-C) (two-way ANOVA interaction of dose and time: F(48,338) = 
13.40, p < 0.0001, for NorBNI Fig 1A and F(48,325) = 14.75, p < 0.0001, for 5′GNTI, Fig 
1B). To determine if these compounds were exerting their effects through KOR, we 
evaluated the itch response in KOR-KO mice. Interestingly, the scratching behavior is still 
present in KOR-KO mice treated with NorBNI (10 mg/kg) or 5′GNTI (1 mg/kg) compared 
to vehicle (Figure D: two-way ANOVA for interaction of treatment and time for NorBNI: 
F(12, 52) = 7.251, p < 0.0001 and 5′GNTI: F(12, 52) = 10.37, p < 0.0001). When the sum of 
the scratching bouts is compared to vehicle (Figure 1E, t-test comparing treatment to 
vehicle: **p < 0.01), it becomes evident that they induce an itch response that is ∼3-4 fold 
over that which is induced by vehicle (shown as fold over vehicle for comparison to WT 
responses in Figure 1F). These findings suggest that a maximal itch response is reached with 
both NorBNI and 5′GNTI and that deletion of KOR significantly ameliorates the response, 
however these agents still promote some itch independent of KOR expression.
3.2 KOR antagonist-induced pruritus is reduced in βarr2-KO mice compared to βarr2-WT 
mice
To examine the role of βarrestin2 in KOR-modulation of pruritus, we examined scratching 
behaviors induced by the KOR antagonists NorBNI and 5′GNTI in βarr2-WT and βarr2-KO 
mice. The KOR antagonists induced itch in both genotypes compared to vehicle (two-way 
ANOVA for dose effect of NorBNI in WT: F(4,360) = 24.43, p < 0.0001, Figure 2A; NorBNI 
in βarr2-KO: F(4,336) = 9.925, p < 0.0001, Figure 2B; 5′GNTI in WT: F(4,372) = 27.72, p < 
0.0001, Figure 2C; 5′GNTI in βarr2-KO: F(4,420) = 23.40, p < 0.0001, Figure 2D). However, 
the response observed in the βarr2-KO mice is not as robust as that observed in the WT 
littermates for either KOR antagonist (two-way ANOVA for genotype: for NorBNI: F(4, 58) 
= 11.10, p = 0.0015; Bonferroni post-hoc analysis, *p < 0.05, Figure 2E; and 5′GNTI: F(1,63) 
= 13.02, p = 0.0006; Bonferroni post-hoc analysis, *p < 0.05, Figure 2F). These studies 
suggest that in the absence of βarrestin2, mice either display less of a scratching response or 
experience less of an induction of itch upon treatment with two different KOR antagonists in 
a dose dependent manner.
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3.3 Chloroquine phosphate-induced pruritus results in no genotype differences in βarr2-
WT and βarr2-KO mice
To test whether the WT and βarr2-KO mice are equally capable of expressing an itch 
response, we tested a general pruritic agent that is not known to be an antagonist at the 
KOR. Chloroquine phosphate (CP) is an antimalarial medication that, upon injection 
subcutaneously, promotes a robust itch response thought to be primarily due to triggering 
mast cell degranulation and a subsequent elevation of inflammatory cytokines as well as 
other itch-producing mediators (Aghahowa et al., 2010); it is often used to induce a model of 
pruritus in mice (Akiyama et al., 2014; Inan and Cowan, 2004). Figure 3 shows that CP-
induced scratching was evident in both genotypes compared to vehicle (two-way ANOVA 
for treatment: WT: F(2,168) = 53.07, p < 0.0001; βarr2-KO: two-way ANOVA: F(2,180) = 
63.28, p < 0.0001, (Figure 3A,B). Two-way ANOVA comparison between genotypes, 
within each dose, did not reveal a genotype effect when analyzed with the 5 minute binning 
data (p > 0.05) or when comparing the sum of the scratching response over the hour testing 
session at each dose (two-way ANOVA for genotype: F(1,28) = 0.00007, p = 0.9931; dose: 
F(2,28) = 132.8, p < 0.0001, Figure 3C) suggesting that the decrease in KOR antagonist-
induced itch responses may be due to the actions of the antagonists at the KOR wherein 
βarrestin2 may play a role.
3.4 KOR agonists suppress antagonist- induced pruritus
KOR agonist pretreatment can prevent KOR antagonist-induced acute pruritus as previously 
demonstrated in ICR mice by use of nalfurafine administration prior to 5′GNTI and 
U50,488H administration before NorBNI (Inan et al., 2011; Kamei and Nagase, 2001). Here 
we show that systemic pretreatment with U50,488H dose-dependently blocks the 
development of NorBNI-induced itch in C57BL/6J mice (two-way ANOVA for dose: 
F(4,360) = 49.23, p < 0.0001 Figure 4A; one-way ANOVA vs. Veh + NorBNI: F(4,29) = 
17.35, p < 0.0001, Figure 4B). Suppression of CP-induced pruritus has also been 
demonstrated using KOR agonist nalfurafine in ICR mice (Inan and Cowan, 2004). Here we 
show systemic pretreatment with U50,488H also dose-dependently blocks the development 
of the CP-induced itch response in C57BL/6J mice (two-way ANOVA for dose: F(3, 276) = 
93.30, p < 0.0001, Fig 4C; one-way ANOVA vs. Veh + CP: F(4,29) = 17.35, p < 0.0001, 
Figure 4D). The suppression of CP-induced scratching by U50,488H is be prevented by a 24 
hour systemic pretreatment of the long-lasting KOR antagonist NorBNI (10 mg/kg, i.p.) 
(two-way ANOVA comparing Veh + U50,488H + CP and NorBNI + U50,488H + CP: 
F(1,96) = 30.42, p < 0.0001, Figure 4E). This is also evident in the comparison of the sum of 
the scratching bouts occurring during the 1 hour test session (NorBNI + Veh + CP vs. Veh + 
U50,488H + CP: **p < 0.01; Veh + U50,488H + CP and NorBNI + U50,488H + CP: ##p > 
0.05, student's t-test) (Figure 4F).
Since our studies in the βarr2-KO mice suggest that antagonism of KOR to induce itch may 
involve βarrestin2, we asked whether βarrestin2 is involved in the agonist-induced 
suppression of the itch response. WT and βarr2-KO mice were treated with U50,488H (1, 3 
mg/kg s.c.) prior to challenge with CP (40 mg/kg, s.c.neck), a dose that produces an 
equivalent scratching response between the genotypes. Compared to vehicle, U50,488H 
suppresses the scratching behaviors in WT (two-way ANOVA for dose effect: F(2,144) = 
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47.14, p < 0.0001, Figure 5A) and βarr2-KO mice (two-way ANOVA for dose effect: 
F(2,144) = 52.96, p < 0.0001, Figure 5B). Two-way ANOVA comparison between genotypes, 
within each dose, did not reveal a genotype effect when analyzed with the 5 minute binning 
data (p > 0.05) or when comparing the sum of the scratching response over the hour testing 
session at each dose (two-way ANOVA for genotype: F(1,24) = 0.02729, p = 0.8702; dose: 
F(2,24) = 138.0, p < 0.0001, Figure 5C) suggesting that βarrestin2 may not be required for 
inducing the antipruritic effects of KOR agonists.
3.5 A KOR agonist that induces bias towards G protein signaling, Isoquinolinone 2.1, 
dose-dependently prevents the development of chloroquine phosphate-induced pruritus 
yet does not induce sedation
Recently, we described the development of KOR agonists that displays bias for G protein 
signaling over βarrestin2 recruitment, a “G protein signaling biased agonist” (Figure 6A) 
(Zhou et al., 2013). Isoquinolinone 2.1 (Iso2.1) dose dependently suppresses the itch 
response induced by CP (40 mg/kg, s.c.neck) (two-way ANOVA for dose: F(2,156) = 49.77, p 
< 0.0001, Figure 6B; one-way ANOVA for 1 hour sums: F(3,22) = 38.98, p < 0.0001, Figure 
6C). The effects of Iso2.1 could be fully blocked by a pretreatment of systemic NorBNI (10 
mg/kg, i.p.) 24 hours prior to Iso2.1 treatment, supporting that Iso2.1 is acting at KOR (two-
way ANOVA comparing Veh + Iso2.1 + CP and NorBNI + Iso2.1 + CP: F(1,96) = 25.21, p < 
0.0001, Figure 6D). A comparison of the sum effects over the one hour test period also 
reveals significant reversal of Iso2.1 effects by NorBNI + Veh + CP vs. Veh + Iso2.1 + CP: 
**p < 0.01; Veh + Iso2.1 + CP and NorBNI + Iso2.1 + CP: ##p > 0.05, student's t-test) 
(Figure 6E).
We then asked whether a G protein-biased KOR agonist would remain potent in the absence 
of βarrestin2. Both WT (two-way ANOVA for dose,: F(2,144) = 20.60, p < 0.0001, Figure 
7A) and βarr2-KO mice (two-way ANOVA for dose: F(2,144) = 26.29, p < 0.0001, Figure 
7B) respond to pretreatment with G protein biased KOR agonist Iso2.1 to reduce the 
development of the CP-induced scratching behavior compared to vehicle treated mice. Two-
way ANOVA comparison between genotypes, within each dose, did not reveal a genotype 
effect when analyzed with the 5 minute binning data (p > 0.05) or when analyzing the sum 
of the response over the hour testing session (two-way ANOVA for genotype: F(1,23) = 
0.2042, p = 0.6556; dose: F(2,23) = 56.80, p < 0.0001) (Figure 7C).
Since KOR agonists are known to suppress locomotor activity, we asked whether Iso2.1 
decreased locomotor activity to a greater degree than U50,488H at the highest dose used to 
suppress the scratching response, with the idea that if Iso2.1 had sedative effects, it may 
result in less CP-induced scratching behavior that would be independent of its direct actions 
at KOR relating to the sensory perception of itch. Spontaneous locomotor activity was 
assessed in the open field following a 3 mg/kg, i.p. injection of U50,488 or Iso2.1 (Figure 
8). While U50,488H significantly suppresses activity (two-way ANOVA vs. vehicle: F(1,132) 
= 13.81, p = 0.0003); Iso2.1 has no significant effect on spontaneous activity (two-way 
ANOVA vs. vehicle: p > 0.05). The effects of U50,488H on locomotor activity are 
prevented with a twenty-four hour pretreatment of NorBNI (10 mg/kg, i.p.) (two-way 
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ANOVA vs 3 mg/kg U50,488H: F(1, 132) = 52.94, p < 0.0001), showing that the effects of 
U50,488H on locomotor activity can be blocked by a KOR antagonist.
4. Discussion
In this study we show that the actions of KOR antagonists, NorBNI and 5′GNTI, dose 
dependently promote a scratching response in C57BL/6J mice when injected s.c. at the nape 
of the neck, confirming observations made in other mouse strains (Figure 1A-C). We also 
show the effects of these antagonists are less severe in the KOR-KO mice, however, the itch 
response that is produced is still significant suggesting that the antagonist effects cannot be 
completely attributed to actions at the KOR (Figure 1D-E). The effects of the KOR 
antagonists were slightly but significantly decreased in the βarr2-KO mice compared to WT 
littermate controls (Figure 2), while the effects of chloroquine phosphate were equivalent in 
both genotypes (Figure 3). A systemic, 24 hour pretreatment with NorBNI reverses the 
effects of U50,488H implicating a KOR-mediated mechanism in the antipruritic effects of 
U50,488H (Figure 4). The ability of NorBNI to reverse the effects of U50,488H in the 
chloroquine phosphate model of pruritus was maintained in the βarr2-KO mice (Figure 5). A 
KOR agonist biased for G protein signaling over βarrestin2 recruitment in cell culture assay, 
Isoquinolinone 2.1, was effective in preventing CP-induced itch (Figure 6); this effect was 
blocked by NorBNI implicating KOR mechanisms are preserved in βarrestin2-KO mice as 
one might anticipate for an agonist that has very low functional affinity for recruiting 
βarrestin2 in cell-based assays (Figure 7). Finally, the suppression of itch induced by Iso2.1 
could not be attributed to increased sedative properties of the biased agonist (Figure 8).
Together these data suggest that 5′GNTI and NorBNI may induce itch via a KOR-dependent 
mechanism, however, they may also exert their effects by nonspecific effects as they 
maintained significant efficacy in the KOR-KO mice. There have also been speculations of 
non-opioid targets (Munro et al., 2013, Zhou et al., 2015, Zhou et al., in press). For example, 
screening against a panel of non-opioid receptors and ion channels reveal 5′GNTI to be a 
weak M1 muscarinic receptor antagonist (Inan et al., 2011; Munro et al., 2013). 
Interestingly, intrathecal treatment with M1 agonist McN-A-343 inhibits 5′GNTI-induced 
pruritus (Inan et al., 2009b). This supports the idea that the residual pruritus produced in 
KOR-KO mice by 5′GNTI could be attributed to antagonism at the M1 muscarinic receptor, 
however, it does not rule out other potential mechanisms of action.
While the data suggest that the βarr2-KO mice may be less sensitive to the antagonists for 
promoting the itch response via KOR, it is difficult to support this conclusion as the 
differences between the WT and βarr2-KO mice may be due to differences in the, pruritic 
effects that persist in the absence of KOR in response to these antagonists. As such, the 
βarr2-KO mice could simply be less responsive to this unidentified effect. Moreover, the 
βarr2-KO mice may be impaired in their ability to display a scratching response compared to 
the WT mice. In an attempt to address these issues, chloroquine phosphate (CP) was used as 
a general pruritic agent. In those studies, CP induced an equivalent itch response in both 
genotypes, arguing against a disruption in the ability to display the response. The general 
mechanism of action of CP, an antimalarial medication, has been attributed to inducing a 
mast cell degranulation resulting in the localized release of inflammatory factors (Aghahowa 
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et al., 2010). NorBNI and 5′GNTI could also be producing nonspecific effects that may or 
may not include the same mechanisms induced by CP. Therefore, it remains difficult to 
attribute the differences seen between the WT and βarr2-KO mice solely to differential 
regulation of KOR.
Aside from investigating the role of βarrestin2, our results contribute to and expand upon 
studies that report KOR antagonists NorBNI and 5′GNTI are pruritogens in mice. NorBNI 
was first described as a pruritogen in ICR mice (Kamei and Nagase, 2001), whereas a 
majority of 5′GNTI-induced pruritus has been characterized in Swiss-Webster mice (Inan et 
al., 2009a, b, 2011). Different strains of mice can inherently have different phenotypes that 
present when challenged with a pruritogen. For example, ICR mice show an increased 
release of histamine from mast cells, which is thought to facilitate scratching behavior, 
whereas the histamine release from mast cells in C57BL/6 mice is relatively low (Toda et 
al., 1989). Our study demonstrates that C57BL/6J adult male mice significantly respond to 
KOR antagonists and CP for the induction of a pruritic response; this will be useful 
information as many genetic mouse models have been developed on the C57BL/6J 
background.
A growing number of studies report that KOR is important in the processing of pruritus 
(Kardon et al., 2014; Ross et al., 2010; Sardella et al., 2011). Additionally, the development 
and characterization of nalfurafine (TRK-820) in the clinic to treat hemodialysis-associated 
pruritus (Kumagai et al., 2012; Kumagai et al., 2010; Ueno et al., 2013; Wikstrom et al., 
2005) supports the therapeutic potential of KOR agonists in treating pruritus. Indeed, there is 
significant evidence supporting activation of KOR as an avenue for the treatment of itch 
arising from multiple pruritic effectors in both rodents (Gmerek and Cowan, 1988; Kamei 
and Nagase, 2001) and non-human primates (Ko and Husbands, 2009; Ko et al., 2003). For 
example, nalfurafine, a 4,5-epoxymorphinan derivative full agonist for KOR and partial 
agonist for the mu opioid receptor (MOR) (Nagase et al., 1998; Seki et al., 1999), has potent 
antipruritic-activity in both antihistamine-effective and -ineffective animal models of 
pruritus. These include pruritus induced by substance P, histamine (Togashi et al., 2002), 
compound 48/80 (Wang et al., 2005), chloroquine (Inan and Cowan, 2004), scratching 
secondary to cholestasis (Inan and Cowan, 2006) and KOR antagonist-induced itch (Inan et 
al., 2009b) all in rodents and intravenously administered morphine in monkeys (Wakasa et 
al., 2004). Nalfurafine (Remitch®) is also clinically utilized in Japan for the treatment of 
patients suffering from uremic pruritus (Kumagai et al., 2012; Kumagai et al., 2010; Ueno et 
al., 2013; Wikstrom et al., 2005). Like nalfurafine, the novel KOR agonist Iso2.1 also 
prevents the development of itch from multiple pruritogens, specifically KOR antagonist-
induced (Figure 3A-B) and chloroquine phosphate-induced pruritus (Figure 3C-D) with a 
similar efficacy as U50,488H.
Iso2.1 possesses high selectivity and affinity for KOR and induces receptor signaling biased 
toward G protein coupling over βarrestin2 recruitment (Zhou et al., 2013). Recently, another 
G protein signaling biased KOR agonist, RB-64, derivative of salvinorin A, was found to 
produce antinociception and conditioned place aversion (CPA) and not motor incoordination 
(White et al., 2014). These results suggest KOR-mediated G protein signaling leads to 
antinociception and CPA, whereas KOR-mediated βarrestin2 signaling may contribute to the 
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motor deficits. Interestingly, Iso2.1 maintained antinociceptive efficacy in a mouse warm 
water tail immersion test (Zhou et al., 2013) while maintaining potency in suppressing CP-
induced pruritus, independent of βarrestin2 (Figures 6 & 7). Whether this biased agonist 
suppresses locomotor coordination like U50,488H does, remains to be fully evaluated; 
however, our studies suggest that it does not suppress spontaneous locomotor activity to a 
greater extent than U50,488H (Figure 8).
It is attractive to speculate that the use of a compound that possesses bias in cell-based 
assays (shows a mathematically derived preference for G protein signaling in one assay over 
βarrestin2 recruitment in another assay as compared to the performance of a reference 
agonist, U69,593 in both assays) can be used to define a preferred signaling pathway in 
vivo. However, this may not necessarily be the case. Cell-based signaling assays used to 
assess whether a compound is biased only provide an opportunity to compare the compound 
to the performance of a reference compound in the context of the assay. The context of the 
assay is the immediate cellular environment, which includes the signaling effectors that are 
available for interaction as well as the thermodynamic exchanges favored by membrane 
compositions and interacting partners. As the cellular environment is assuredly different 
between cell-based assay systems and endogenous sensory neurons, one cannot simply infer 
that the bias observed in cell culture will directly translate to the exact recapitulation of bias 
in the endogenous setting (Zhou and Bohn, 2014). However, the cell-based assay systems 
serve as very useful models in determining how compounds differ from the way a 
conventional agonist or endogenous hormone functions in vivo. Future studies, and likely, 
the development of better assay tools, are needed to determine the actual signal that 
propagates from KOR in its modulation of pruritus. However, as compounds with diverse 
chemotypes that share classifications among the cell-based systems venture into the 
endogenous setting, correlations will become apparent and inform as to the pharmacological 
properties that may translate from in vitro characterizations to behavioral modulations.
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• KOR agonists are clinically used for pruritis yet most KOR agonists induce 
sedation.
• G protein/βarrestin2 biased KOR agonists are antipruritic yet not sedating in 
mice.
• Biased KOR agonists may have therapeutic utility in treating pruritis.
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NorBNI and 5′GNTI induce scratching behaviors in C57BL/6J mice with some response 
still present in KOR-KO mice. (A) NorBNI (1.0-10 mg/kg, s.c.neck) and (B) 5′GNTI (0.1-1.0 
mg/kg, s.c.neck) induce scratching behaviors over a 1 hour period compared to vehicle (two-
way ANOVA for interaction of dose and time (p < 0.0001) for both; Vehicle n = 10; all 
other groups n = 5-6). (C) The sum of the total number of scratching bouts over the hour 
session is presented for each dose. (D) KOR-KO mice display scratching behaviors in 
response to NorBNI (10 mg/kg, s.c.neck) and 5′GNTI (0.1 mg/kg, s.c.neck) compared to 
vehicle (two-way ANOVA for interaction of treatment and time (p < 0.0001) for both; n = 3 
all groups). (E) The sum of the scratching bouts over the hour session for KOR-KO reveals 
a significant effect of the KOR antagonists in the absence of KOR (t-test comparing 
treatment to vehicle, **p < 0.01; n = 3 all groups). (F) For visualization comparison, the fold 
stimulation over vehicle comparison of the antagonist effects presented in C and F are 
shown. Data are presented as mean ± SEM.
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βarr2-KO mice are less responsive to NorBNI and 5′GNTI. (A) WT and (B) βarr2-KO mice 
display a dose-dependent scratching response to NorBNI (s.c.neck) compared to vehicle 
(WT: two-way ANOVA for dose, p < 0.0001; n = 6-8; βarr2-KO: two-way ANOVA for 
dose, p < 0.0001; n = 6-8) as well as to 5′GNTI (C) WT and (D) barr2-KO mice display a 
dose-dependent response to 5′GNTI (s.c.neck) compared to vehicle (WT: two-way ANOVA 
for dose, p < 0.0001; n = 7-8; βarr2-KO: two-way ANOVA for dose, p < 0.0001; n = 7-8). 
(E) Comparison of the sum of dose effects over the hour test period, WT mice display a 
significantly greater response to NorBNI than barr2-KO mice (two-way ANOVA for 
genotype (p = 0.0015) and dose (p < 0.0001), *p<0.05 Bonferroni post hoc analysis; n = 
6-8). (F) Comparison of the sum of dose effects over the hour test period, WT mice display 
a significantly greater response to 5′GNTI than βarr2-KO mice (two-way ANOVA for 
genotype (p = 0.0006) and dose (p < 0.0001), *p < 0.05 Bonferroni post hoc analysis; n = 
7-8). Data presented as mean ± SEM.
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WT and βarr2-KO mice display equally robust scratching behaviors in response to 
administration of the general pruritic agent, chloroquine phosphate (CP). (A, B) CP (20, 40 
mg/kg, s.cneck) induces itch in WT and βarr2-KO mice (two-way ANOVA for dose, p < 
0.0001 for both WT and βarr2-KO genotypes; WT, Vehicle n = 7, CP n = 5 for both doses; 
βarr2-KO, Veh n = 8, CP n = 5 for both doses). Two-way ANOVA comparison between 
genotypes, within each dose including vehicle, did not reveal a genotype effect when 
analyzed with the 5 minute binning data (p > 0.05). (C) Comparison of the sum of the 
response over the hour testing session at each dose revealed a significant effect of dose with 
no difference between the genotypes (two-way ANOVA for genotype and dose (p < 0.0001), 
***p < 0.001, ****p < 0.0001 Bonferroni post hoc analysis). Data are presented as mean ± 
SEM.
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A balanced kappa agonist suppresses scratching behaviors induced by NorBNI and 
chloroquine phosphate in C57BL/6J mice. (A, B) U50,488H (0.1 - 3.0 mg/kg, s.c.) 
administered 10 minutes prior to NorBNI (5 mg/kg, s.c.neck) suppresses the antagonist-
induced scratching response. For the vehicle response, vehicle (s.c.) was administered 10 
min prior to a challenge with vehicle (s.c.neck). (A) Dose effect over the time course 
compared to vehicle: two-way ANOVA for dose (p < 0.0001); Vehicle, n = 11; all other 
groups, n = 5-7. (B) Sum of the response over the hour test session: one-way ANOVA vs. 
Veh + NorBNI (p < 0.0001), ***p < 0.001, ****p < 0.0001 Bonferroni post hoc analysis. 
(C, D) U50,488H (1.0 and 3.0 mg/kg, s.c.) administered 10 minutes prior to CP (40 mg/kg, 
s.c.neck) suppresses the scratching response. For the vehicle response, vehicle (s.c.) was 
administered 10 min prior to a challenge with vehicle (s.c.neck). (C) Dose effect over the 
time course compared to vehicle: two-way ANOVA for dose (p < 0.0001); Vehicle, n = 11; 
all other groups, n = 6-7. (D) Sum of the response over the hour test session: one-way 
ANOVA vs. Veh + CP (p < 0.0001), ****p < 0.0001 Bonferroni post hoc analysis. (E, F) 
Twenty-four hour pretreatment with kappa antagonist NorBNI blocks the antipruritic effects 
of U50,488H on CP-induced itch. (E) Effect of Veh (i.p.) + U50,488H (1 mg/kg, s.c.) + CP 
(40 mg/kg, s.c.neck) vs. NorBNI (10 mg/kg, i.p.) + U50,488H (1 mg/kg, s.c.) + CP (40 
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mg/kg, s.c.neck): two-way ANOVA (p < 0.0001). There were no differences detected 
between vehicle pretreatment and NorBNI pretreatment groups (p > 0.05). (F) The 
comparison of the sum of the responses over the hour test session reveals suppression of CP-
induced itch by systemic U50,488H injection and reversal of U50,488H effects by the 24 
hour pretreatment with NorBNI: one-way ANOVA, ****p < 0.0001 Bonferroni post hoc 
analysis compared to vehicle pretreatment. Data are presented as the mean ± SEM.
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The KOR agonist U50,488H suppresses scratching behaviors induced by chloroquine 
phosphate independent of the presence of βarr-2. (A) U50,488H (1.0 and 3.0 mg/kg, s.c.) 
administered 10 minutes prior to CP (40 mg/kg, s.c.neck) suppresses the scratching response 
in both genotypes. For the vehicle response, vehicle (s.c.) was administered 10 min prior to a 
challenge with vehicle (s.c.neck). Compared to vehicle: (A) WT: two-way ANOVA for dose 
(p < 0.0001); (B) βarr2-KO: two-way ANOVA for dose p < 0.0001); all groups, both 
genotypes n = 5. Two-way ANOVA comparison between genotypes, within each dose, did 
not reveal a genotype effect when analyzed with the 5 minute binning data (p > 0.05). (C) 
Comparison of the sum of the response over the hour testing session at each dose revealed a 
significant effect of dose, but no difference between the genotypes (two-way ANOVA for 
genotype (p > 0.05), and dose (p < 0.0001), ****p < 0.0001 Bonferroni post hoc analysis; 
all groups, both genotypes n = 5). Data are presented as mean ± SEM.
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A KOR agonist that is biased towards G protein signaling over βarrestin2 recruitment 
suppresses chloroquine phosphate-induced itch. (A). Isoquinolinone 2.1 (Iso2.1) is a highly 
selective KOR agonist; †affinity measures for radioligand binding are from Zhou et al., 
2013. (B) Iso2.1 (1.0 and 3.0 mg/kg, s.c.) administered 10 minutes prior to CP (40 mg/kg, 
s.c.neck) suppresses the scratching response compared to vehicle: two-way ANOVA for dose 
(p < 0.0001); n = 5 - 6. (C) Significance is also revealed by the comparison of the sum of the 
response over the hour test session: one-way ANOVA, ***p < 0.001, ****p < 0.0001 
Bonferroni post hoc analysis; n = 5-6). (D, E), Twenty-four hour pretreatment with KOR 
antagonist NorBNI (10 mg/kg, i.p.) blocks the antipruritic effects of Iso2.1 (1 mg/kg, i.p.) on 
CP-induced itch. (D) Effect of Veh + Iso2.1 + CP vs. NorBNI + Iso2.1 + CP: two-way 
ANOVA (p < 0.0001). There were no differences detected between vehicle pretreatment and 
NorBNI pretreatment groups (p > 0.05). (E) The comparison of the sum of the responses 
over the hour test session reveals suppression of CP-induced itch by systemic Iso2.1 
injection and reversal of Iso2.1 effects by the 24 hour pretreatment with systemic NorBNI: 
one-way ANOVA, NorBNI + Veh + CP vs. Veh + Iso2.1 + CP, **p < 0.01; NorBNI + 
Iso2.1 + CP vs. Veh + Iso2.1 + CP, #p < 0.05, student's t-test. Data are presented as the 
mean ± SEM.
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A G protein biased KOR agonist remains potent in the absence of βarr-2. (A) Iso2.1 (1 and 3 
mg/kg, s.c.) administered 10 minutes prior to CP (40 mg/kg, s.c.neck) suppresses the 
scratching response in both genotypes. Compared to vehicle: (B) WT: two-way ANOVA for 
dose (p < 0.0001); βarr2-KO: (p < 0.0001); all groups, both genotypes n = 5. Two-way 
ANOVA comparison between genotypes, within each dose, did not reveal a genotype effect 
when analyzed with the 5 minute binning data (p > 0.05). (C) Comparison of the sum of the 
response over the hour testing session at each dose revealed a significant effect of dose, but 
no difference between the genotypes: two-way ANOVA for genotype (p > 0.05), and dose 
(p < 0.0001), ****p < 0.0001 Bonferroni post hoc analysis; all groups, both genotypes n = 5. 
Data are presented as mean ± SEM.
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A G protein biased KOR agonist does suppress spontaneous locomotor activity. While 
U50,488H (3 mg/kg, s.c.) significantly suppressed activity (two way ANOVA vs. vehicle, p 
= 0.0003), Iso2.1 (3 mg/kg, s.c.) had no significant effect on spontaneous activity when 
compared to vehicle (two-way ANOVA vs. vehicle, p>0.05). Twenty-four hour pretreatment 
with NorBNI (10 mg/kg, i.p.) prevented the decreased locomotor activity associated with 
U50,488H (two-way ANOVA vs. 3 mg/kg U50488H, p < 0.0001). Vehicle, n = 9; Iso2.1, n 
= 6; U50,488H, n = 7; NorBNI + U50,488H, n = 6. Data presented as mean ± SEM.
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